High-Throughput. Low-Cost. Reliable Supply.

The novel coronavirus SARS-CoV-2 pandemic has created an enormous challenge for health systems, clinical laboratories, public health officials, and communities worldwide. Testing shortages remain a bottleneck in the battle to curtail COVID-19 spread and it is crucial to establish a reliable supply of low-cost tests.

In response to these challenges, Agena Bioscience® developed an accurate and high-throughput diagnostic test on its MassARRAY® System. Our mission remains clear: to equip genomic and clinical testing laboratories with practical solutions that increase productivity and lower costs.

As emphasized by public health leaders, more scalable testing needs to be accessible to get ahead of the COVID-19 spread and Agena is uniquely situated to deliver millions of tests per month to support clinical laboratories around the globe.

pete-dansky-ceo-01“We are excited to offer a truly scalable platform to support the need for high-throughput SARS-CoV-2 testing. To address the crisis presented by COVID-19, labs need to cost-effectively process large numbers of samples. The MassARRAY is the perfect tool for that.” –Pete Dansky, Agena CEO

The MassARRAY® SARS-CoV-2 Panel

The MassARRAY® SARS-CoV-2 Panel is available for in vitro diagnostic use under Emergency Use Authorization by the U.S. FDA. It is CE-IVD marked in Europe.

  • HIGH-THROUGHPUT - Process up to thousands of samples per day with a single MassARRAY System
  • COST-EFFECTIVE - Low-cost reagents and automated results reporting saves lab resources
  • RELIABLE SUPPLY - Overcome instrument and reagent shortages with a reliable supply

The MassARRAY® SARS-CoV-2 Panel is now available. Get started by completing the form – we will respond quickly to understand your needs.

Access information for Healthcare Providers and Patients.


MassARRAY System for SARS TestingMassARRAY® System

The MassARRAY technology is a benchtop system that provides timely and accurate analysis of up to thousands of clinically relevant variants in a single workflow. For SARS-CoV-2, our technology enables accurate detection with comprehensive coverage. Moreover, the ability to analyze multiple variants in a single assay reduces per sample cost, scaling your throughput and optimizing supply and resource requirements.

Additional Resources:

United States: For in vitro diagnostic use under Emergency Use Authorization by the U.S. FDA.
Europe: CE-IVD marked and intended for in vitro diagnostic use in Europe.
For other regions please see our SARS-CoV-2 Research Use Panel.

Get Started Now

We will quickly respond to get you started with the MassARRAY® SARS-CoV-2 Panel.